Jennison Associates
ALLO icon

Jennison Associates’s Allogene Therapeutics ALLO Stock Holding History

Jennison Associates’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-829,728
Closed -$24M – 645
2019
Q1 		$24M Sell
829,728
-364
-0% -$10.6K 0.02% 329
2018
Q4 		$22.2M Buy
+830,092
New +$22.1M 0.02% 339

Other funds holding ALLO

TGHSA
TPG Group Holdings (SBS) Advisors Fort Worth, Texas $10.1B AUM 22.58% 1-Year Est. Return
VM
VV Manager Boston, Massachusetts $114M AUM 59.16% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Jennison Associates's ALLO Position: Q2 2019 in Review

Jennison Associates sold out of Allogene Therapeutics (ALLO) in Q2 2019, closing a stake of 829,728 shares — an estimated $24M sold.

Jennison Associates first reported a position in ALLO in Q4 2018 and held it in 2 quarters. The position peaked at $24M in Q1 2019. 94 funds tracked by Wall St. Rank hold ALLO as of Q2 2019.

  • Jennison Associates reported no remaining Allogene Therapeutics position as of Q2 2019 after selling out during the quarter.
  • Jennison Associates sold 829,728 Allogene Therapeutics shares in Q2 2019, an estimated $24M.
  • Jennison Associates first reported a position in Allogene Therapeutics in Q4 2018 and held it in 2 quarters.
  • Jennison Associates's Allogene Therapeutics position peaked at $24M in Q1 2019.
  • 94 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q2 2019.

Based on Jennison Associates's 13F filing for Q2 2019, filed 6 Aug 2019.